Patents by Inventor Stephane Perreault
Stephane Perreault has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10479770Abstract: The present application provides the compounds of formula I or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein t, R1, R2, R3, R4, and R6 are as described herein.Type: GrantFiled: September 21, 2017Date of Patent: November 19, 2019Assignee: Gilead Sciences, Inc.Inventors: Jayaraman Chandrasekhar, Devan Naduthambi, Leena Patel, Stephane Perreault, Gary Phillips, Kassandra F. Sedillo, Nicholas Alexander Till, Jennifer Anne Treiberg, William J. Watkins, Julian A. Codelli, Joshua J. Van Veldhuizen
-
Patent number: 10308639Abstract: The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein X, Y, Z, n, m?, A?, R1, R2, and R3 are described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts, isomers, tautomer, or mixture thereof, and methods of using these compounds and compositions for treating conditions mediated by one or more PI3K isoforms.Type: GrantFiled: June 10, 2015Date of Patent: June 4, 2019Assignee: Gilead Sciences, Inc.Inventors: Jerry Evarts, Joshua Kaplan, Leena Patel, Stephane Perreault, Barton W. Phillips, Gary Phillips, Jennifer A. Treiberg, Suet Chung Yeung
-
Patent number: 10227350Abstract: The present application provides the compounds of formula I or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein s, t, n, R1, R2, R3, R4, R5, and R6 are as described herein.Type: GrantFiled: September 21, 2017Date of Patent: March 12, 2019Assignee: Gilead Sciences, Inc.Inventors: Jayaraman Chandrasekhar, Leena Patel, Stephane Perreault, Gary Phillips, Nicholas Alexander Till, Jennifer Anne Treiberg
-
Patent number: 10221197Abstract: The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, or a mixture thereof, wherein n, m, q, A?, W1, W2, W3, R1, R2, and R3 are described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or mixture thereof, and methods of using these compounds and compositions for treating conditions mediated by one or more PI3K isoforms.Type: GrantFiled: June 10, 2015Date of Patent: March 5, 2019Assignee: Gilead Sciences, Inc.Inventors: Zhimin Du, Jerry Evarts, Joshua Kaplan, Musong Kim, Devan Naduthambi, Leena Patel, Stephane Perreault, Barton W. Phillips, Gary Phillips, Kirk L. Stevens, Jennifer A. Treiberg, Joshua Van Veldhuizen, William J. Watkins, Suet Chung Yeung
-
Patent number: 10214519Abstract: The present application provides the compounds of formula I or IA or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein s, t, m, n, R1, R2, R3, R4, R5, R6 and R7 are as described herein.Type: GrantFiled: September 21, 2017Date of Patent: February 26, 2019Assignee: Gilead Sciences, Inc.Inventors: Jayaraman Chandrasekhar, Julian Andrew Codelli, Devan Naduthambi, Leena Patel, Stephane Perreault, Gary Phillips, Kassandra F. Sedillo, Jennifer Anne Treiberg, Joshua Van Veldhuizen, William J. Watkins
-
Publication number: 20180086747Abstract: The present application provides the compounds of formula I or IA or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein s, t, m, n, R1, R2, R3, R4, R5, R6 and R7 are as described herein.Type: ApplicationFiled: September 21, 2017Publication date: March 29, 2018Inventors: Jayaraman Chandrasekhar, Julian Andrew Codelli, Devan Naduthambi, Leena Patel, Stephane Perreault, Gary Phillips, Kassandra F. Sedillo, Jennifer Anne Treiberg, Joshua Van Veldhuizen, William J. Watkins
-
Publication number: 20180086768Abstract: The present application provides the compounds of formula I or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein s, t, n, R1, R2, R3, R4, R5, and R6 are as described herein.Type: ApplicationFiled: September 21, 2017Publication date: March 29, 2018Inventors: Jayaraman Chandrasekhar, Leena Patel, Stephane Perreault, Gary Phillips, Nicholas Alexander Till, Jennifer Anne Treiberg
-
Publication number: 20180086719Abstract: The present application provides the compounds of formula I or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein t, R1, R2, R3, R4, and R6 are as described herein.Type: ApplicationFiled: September 21, 2017Publication date: March 29, 2018Inventors: Jayaraman Chandrasekhar, Devan Naduthambi, Leena Patel, Stephane Perreault, Gary Phillips, Kassandra F. Sedillo, Nicholas Alexander Till, Jennifer Anne Treiberg, William J. Watkins
-
Publication number: 20180065953Abstract: The present disclosure provides phosphatidylinositol 3-kinase (PI3K) inhibitors of formula (J), or pharmaceutically acceptable salts thereof, in which A, n, m, R1, R2, R3, R4, R5, R6 and R7 are as defined herein. These compounds are useful for treatment of conditions mediated by one or more PI3K isoforms. The present disclosure further provides pharmaceutical compositions that include a compound of formula (J), or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by one or more PI3K isoforms.Type: ApplicationFiled: August 17, 2017Publication date: March 8, 2018Inventors: Jerry Evarts, Joshua A. Kaplan, Musong Kim, Devan Naduthambi, Leena Patel, Stephane Perreault, Gary Phillips, Lafe J. Purvis, II, Kirk L. Stevens, Jennifer Anne Treiberg
-
Patent number: 9765060Abstract: The present disclosure provides phosphatidylinositol 3-kinase (PI3K) inhibitors of formula (J), or pharmaceutically acceptable salts thereof, in which A, n, m, R1, R2, R3, R4, R5, R6 and R7 are as defined herein. These compounds are useful for treatment of conditions mediated by one or more PI3K isoforms. The present disclosure further provides pharmaceutical compositions that include a compound of formula (J), or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by one or more PI3K isoforms.Type: GrantFiled: June 23, 2015Date of Patent: September 19, 2017Assignee: GILEAD SCIENCES, INC.Inventors: Jerry Evarts, Joshua Kaplan, Musong Kim, Devan Naduthambi, Leena Patel, Stephane Perreault, Gary Phillips, Lafe J. Purvis, II, Kirk L. Stevens, Jennifer A. Treiberg
-
Patent number: 9499523Abstract: The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein n, m, R1, R2, R3, R4, and R5 are described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts, isomers, tautomer, or mixture thereof, and methods of using these compounds and compositions for treating conditions mediated by one or more PI3K isoforms.Type: GrantFiled: June 10, 2015Date of Patent: November 22, 2016Assignee: GILEAD SCIENCES, INC.Inventors: Musong Kim, Stephane Perreault, Suet Chung Yeung
-
Patent number: 9266878Abstract: The present disclosure provides phosphatidylinositol 3-kinase (PI3K) inhibitors of formula (I), or pharmaceutically acceptable salts thereof, in which R1, R2, n, R3, R4, R5 and R6 are as defined herein. These compounds are useful for treatment of conditions mediated by one or more PI3K isoforms, such as PI3K?. The present disclosure further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by one or more PI3K isoforms, such as PI3K?.Type: GrantFiled: April 14, 2015Date of Patent: February 23, 2016Assignee: Gilead Calistoga LLCInventors: Jerry Evarts, Leena Patel, Jennifer A. Treiberg, Stephane Perreault, Arthur Yeung, Lafe J. Purvis, II, Musong Kim
-
Publication number: 20160039793Abstract: The present disclosure provides phosphatidylinositol 3-kinase (PI3K) inhibitors of formula (I), or pharmaceutically acceptable salts or isomers thereof, in which n, m, R1, R2, R4, and R3 are as defined herein. These compounds are useful for treatment of conditions mediated by one or more PI3K isoforms, such as PI3K?. The present disclosure further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts or isomers thereof, and methods of using these compounds and compositions to treat conditions mediated by one or more PI3K isoforms, such as PI3K?.Type: ApplicationFiled: October 21, 2015Publication date: February 11, 2016Inventors: Jerry Evarts, Joshua Kaplan, Musong Kim, Leena Patel, Stephane Perreault, Gary Phillips, Jennifer A. Treiberg, Joshua Van Veldhuizen
-
Publication number: 20160024054Abstract: The present disclosure provides phosphatidylinositol 3-kinase (PBK) inhibitors of formula (J), or pharmaceutically acceptable salts thereof, in which A, n, m, R1, R2, R3, R4, R5, R6 and R7 are as defined herein. These compounds are useful for treatment of conditions mediated by one or more PI3K isoforms. The present disclosure further provides pharmaceutical compositions that include a compound of formula (J), or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by one or more PI3K isoforms.Type: ApplicationFiled: June 23, 2015Publication date: January 28, 2016Inventors: Jerry Evarts, Joshua Kaplan, Musong Kim, Devan Naduthambi, Leena Patel, Stephane Perreault, Gary Phillips, Lafe J. Purvis, II, Kirk L. Stevens, Jennifer A. Treiberg
-
Publication number: 20160016915Abstract: The present disclosure provides phosphatidylinositol 3-kinase (PI3K) inhibitors of formula (I), or pharmaceutically acceptable salts thereof, in which n, m, R1, R2, and R3 are as defined herein. These compounds are useful for treatment of conditions mediated by one or more PI3K isoforms, such as PI3K?. The present disclosure further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by one or more PI3K isoforms, such as PI3K?.Type: ApplicationFiled: May 6, 2015Publication date: January 21, 2016Inventors: Jerry Evarts, Leena Patel, Joshua Kaplan, Jennifer A. Treiberg, Stephane Perreault, Gary Phillips
-
Patent number: 9221795Abstract: The present disclosure provides phosphatidylinositol 3-kinase (PI3K) inhibitors of formula (I), or pharmaceutically acceptable salts or isomers thereof, in which n, m, R1, R2, R4, and R3 are as defined herein. These compounds are useful for treatment of conditions mediated by one or more PI3K isoforms, such as PI3K?. The present disclosure further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts or isomers thereof, and methods of using these compounds and compositions to treat conditions mediated by one or more PI3K isoforms, such as PI3K?.Type: GrantFiled: June 13, 2014Date of Patent: December 29, 2015Assignee: Gilead Sciences, Inc.Inventors: Jerry Evarts, Joshua Kaplan, Musong Kim, Leena Patel, Stephane Perreault, Gary Phillips, Jennifer A. Treiberg, Joshua Van Veldhuizen
-
Publication number: 20150361070Abstract: The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein X, Y, Z, n, m?, A?, R1, R2, and R3 are described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts, isomers, tautomer, or mixture thereof, and methods of using these compounds and compositions for treating conditions mediated by one or more PI3K isoforms.Type: ApplicationFiled: June 10, 2015Publication date: December 17, 2015Inventors: Jerry Evarts, Joshua Kaplan, Leena Patel, Stephane Perreault, Barton W. Phillips, Gary Phillips, Jennifer A. Treiberg, Suet Chung Yeung
-
Publication number: 20150361095Abstract: The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, or a mixture thereof, wherein n, m, q, A?, W1, W2, W3, R1, R2, and R3 are described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or mixture thereof, and methods of using these compounds and compositions for treating conditions mediated by one or more PI3K isoforms.Type: ApplicationFiled: June 10, 2015Publication date: December 17, 2015Inventors: Zhimin Du, Jerry Evarts, Joshua Kaplan, Musong Kim, Devan Naduthambi, Leena Patel, Stephane Perreault, Barton W. Phillips, Gary Phillips, Kirk L. Stevens, Jennifer A. Treiberg, Joshua Van Veldhuizen, William J. Watkins, Suet Chung Yeung
-
Publication number: 20150361071Abstract: The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein n, m, R1, R2, R3, R4, and R5 are described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts, isomers, tautomer, or mixture thereof, and methods of using these compounds and compositions for treating conditions mediated by one or more PI3K isoforms.Type: ApplicationFiled: June 10, 2015Publication date: December 17, 2015Inventors: Musong Kim, Stephane Perreault, Suet Chung Yeung
-
Publication number: 20150218154Abstract: The present disclosure provides phosphatidylinositol 3-kinase (PI3K) inhibitors of formula (I), or pharmaceutically acceptable salts thereof, in which R1, R2, n, R3, R4, R5 and R6 are as defined herein. These compounds are useful for treatment of conditions mediated by one or more PI3K isoforms, such as PI3K?. The present disclosure further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by one or more PI3K isoforms, such as PI3K?.Type: ApplicationFiled: April 14, 2015Publication date: August 6, 2015Applicant: Gilead Calistoga LLCInventors: Jerry Evarts, Leena Patel, Jennifer A. Treiberg, Stephane Perreault, Arthur Yeung, Lafe J. Purvis, II, Musong Kim